Vitamin D3 for Life

Live Enlightened

Article

Intestinal VDR, Barrier Function and Microbial Metabolism: Study Summary

Previous related pageIntestinal VDR, Barrier Function and Microbial Metabolism: Full Evidence ReviewNext related pageVitamin D and Epithelial Barrier Failure Across Gut, Lung and Skin: Full Evidence Review
Study at a glance

How were vitamin D signals, the gut lining and gut microbes studied?

Cell and animal experiments examined vitamin D receptor signals, the intestinal lining and gut microbes. Two small human trials tested vitamin D supplements. Removing a receptor, giving active hormone or using a drug that activates the receptor is different from giving a nutritional supplement to a person.

How did vitamin D signals affect the gut lining in animals?

Low vitamin D or receptor loss worsened intestinal injury caused by chemicals in mice, including leakage of a test substance through the lining. Other experiments supported protective responses involving selected chains of signals inside cells. In injured rats, active vitamin D partly improved measurements of cell replacement and the gut barrier. Removing the receptor also changed selected microbes and their products, with results depending on tissue, diet and sex.

Did supplements improve the gut lining or microbes in people?

A three-month trial in 27 people with Crohn’s disease in remission found no clear difference between vitamin D and placebo in permeability (how easily substances passed through the intestinal lining), inflammatory or defence markers, disease activity or quality of life. A separate trial analysing 41 mostly young, healthy adults found some microbial changes. It did not demonstrate improved barrier function or less inflammation throughout the body.

Do these studies show one proven route to better gut health?

The animal studies did not establish every proposed mechanism or measure the entire process of replacing intestinal cells. In the healthy-adult trial, differences in gut microbes at the start, other gummy ingredients and conflicting descriptions of when treatment was given limited interpretation. Regrouping Crohn’s participants by their final vitamin D levels did not establish a treatment target. These studies do not show one proven chain from supplements to healthier microbes, a better barrier and reduced inflammation.

Read the full article below ↓

Intestinal vitamin D receptor experiments connect signalling with measured permeability, epithelial renewal and microbial metabolism. Human supplementation trials test separate parts of that relationship. For the full methods and comparison, see Intestinal VDR, Barrier Function and Microbial Metabolism: Full Evidence Review.

Experimental barrier and renewal findings

Li and colleagues found that vitamin D deficiency or whole-body VDR loss worsened chemical colitis in mice, including fluorescent-tracer leakage and junction-protein disruption. Receptor activation and Notch inhibition in epithelial models supported a partly Notch-dependent response. Promoter reporters and predicted binding sequences did not directly establish native VDR binding to the Notch-1 promoter. The work used experimental injury and an active receptor agonist, not a human nutritional treatment.

Wang’s separate rat study measured proliferation, apoptosis-related staining, labelled-cell distribution and permeability during chemically induced liver injury. Calcitriol partly improved these outcomes. The findings address renewal and barrier function, but do not establish a complete replacement rate or prove the proposed HO-1 mechanism. These distinctions matter for Vitamin D and Barrier Immunity.

Microbial profiles and immune context

Chatterjee’s conditional receptor-deletion experiments showed tissue-, diet: and sex-dependent changes in faecal metabolites and selected microbes. The study does not establish that a changed microbial product caused systemic inflammation or that supplementation produces a healthier human microbiome. Exploratory statistical thresholds and conflicting directions for selected metabolites further limit specific mechanistic claims. Vitamin D and Mucosal Defence and Vitamin D and Immune Modulation provide the relevant context.

Human comparisons remain limited

Raftery’s placebo-controlled trial of twenty-seven people with Crohn’s disease in remission found no significant between-group difference in permeability, LL-37, CRP, faecal calprotectin, disease activity or quality of life after three months. More favourable results when participants were regrouped by achieved vitamin D status no longer preserved randomisation and did not establish a blood-level target.

Wyatt’s placebo-controlled trial analysed forty-one mostly young, healthy adults and reported community and taxon changes. Baseline differences, different gummy ingredients and conflicting supplementation timelines limit interpretation. It did not demonstrate improved permeability or reduced systemic inflammation. A microbial change is not itself a validated clinical benefit.

Conclusion

The studies support specific experimental links among receptor signalling, barrier organisation and microbial metabolism. They do not establish supplementation-driven improvement in a human microbiome, barrier function and systemic inflammation as one causal chain. Vitamin D and Inflammatory Signalling helps distinguish those different endpoints.

Sources and publication details

Vitamin D/vitamin D receptor protects intestinal barrier against colitis by positively regulating Notch pathway. Li Y and colleagues. Frontiers in Pharmacology. 2024;15:1421577. DOI: 10.3389/fphar.2024.1421577. PMID: 39130644.

Vitamin D receptor promotes healthy microbial metabolites and microbiome. Chatterjee I and colleagues. Scientific Reports. 2020;10:7340. DOI: 10.1038/s41598-020-64226-7. PMID: 32355205.

Vitamin D Improves Intestinal Barrier Function in Cirrhosis Rats by Upregulating Heme Oxygenase-1 Expression. Wang P and colleagues. Biomolecules & Therapeutics. 2019;27(2):222 to 230. DOI: 10.4062/biomolther.2018.052. PMID: 30173501.

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. Raftery T and colleagues. United European Gastroenterology Journal. 2015;3(3):294 to 302. DOI: 10.1177/2050640615572176. PMID: 26137304.

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults. Wyatt M and colleagues. Microbiology Spectrum. 2024;12(10):e00083-24. DOI: 10.1128/spectrum.00083-24. PMID: 39189761.

Related reading

Original sources

Source

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study

Published in Raftery T and colleagues. United European Gastroenterology Journal (2015).

Publication details

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. Raftery T and colleagues. United European Gastroenterology Journal. 2015;3(3):294 to 302. DOI: 10.1177/2050640615572176. PMID: 26137304.

Read more →
Source

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults

We conducted a double-blind, randomized, placebo-controlled trial to identify the acute and long-term microbiota structural and metabolite changes that occur in response to a moderate dose (4,000 IU) of vitamin D3 for 12 weeks in healthy adults.

Publication details

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults. Wyatt M and colleagues. Microbiology Spectrum. 2024;12(10):e00083-24. DOI: 10.1128/spectrum.00083-24. PMID: 39189761.

Read more →